Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Buys 73,953 Shares of Stock

Posted by Francis Steltz on Apr 21st, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc acquired 73,953 shares of the business’s stock in a transaction that occurred on Wednesday, April 16th. The shares were bought at an average price of $11.16 per share, with a total value of $825,315.48. Following the completion of the purchase, the director now owns 17,773,727 shares in the company, valued at $198,354,793.32. This trade represents a 0.42 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Friday, April 4th, Ecor1 Capital, Llc purchased 196,438 shares of Zymeworks stock. The shares were purchased at an average cost of $11.17 per share, for a total transaction of $2,194,212.46.
On Wednesday, April 2nd, Ecor1 Capital, Llc acquired 74,360 shares of Zymeworks stock. The shares were purchased at an average price of $11.85 per share, for a total transaction of $881,166.00.
On Monday, March 31st, Ecor1 Capital, Llc bought 4,397 shares of Zymeworks stock. The stock was purchased at an average cost of $11.75 per share, with a total value of $51,664.75.
On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The stock was acquired at an average price of $12.24 per share, for a total transaction of $536,699.52.
On Monday, March 24th, Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock. The shares were acquired at an average cost of $13.08 per share, for a total transaction of $296,772.12.
On Friday, March 21st, Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock. The shares were bought at an average cost of $12.78 per share, with a total value of $396,601.74.
On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The shares were bought at an average price of $12.64 per share, with a total value of $736,987.84.
On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The shares were bought at an average cost of $12.23 per share, with a total value of $688,267.71.
On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, for a total transaction of $5,845,082.88.
On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The stock was purchased at an average price of $11.49 per share, for a total transaction of $3,684,728.10.

Zymeworks Trading Up 2.5 %

Shares of ZYME opened at $11.53 on Monday. The company’s fifty day simple moving average is $12.38 and its 200-day simple moving average is $13.53. The company has a market cap of $802.22 million, a P/E ratio of -7.69 and a beta of 1.18. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its position in shares of Zymeworks by 1.2% during the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock valued at $22,645,000 after buying an additional 17,849 shares during the period. State Street Corp lifted its stake in shares of Zymeworks by 6.1% during the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after acquiring an additional 67,401 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Zymeworks by 14.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company’s stock valued at $14,240,000 after acquiring an additional 123,240 shares during the period. Bridgeway Capital Management LLC increased its stake in Zymeworks by 2.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company’s stock worth $11,121,000 after purchasing an additional 17,092 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock worth $9,403,000 after purchasing an additional 311,107 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on ZYME shares. Lifesci Capital began coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, March 10th. Finally, Citigroup upped their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $21.00.

View Our Latest Research Report on ZYME

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.